Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study

International Journal of Urology

Volumn 9, Issue 1, 2002, Pages 42-46

  Kojima, Munekado ^a   Kamoi, Kazumi ^a   Ukimura, Osamu ^a   Fujito, Akira ^a   Nakao, Masahiro ^a   Tanaka, Shigeki ^a   Miyashita, Hiroaki ^a   Iwamoto, Noriyuki ^a   Ohe, Hiroshi ^a   Kitamori, Tomohito ^a   Date, Seiki ^a   Kitamura, Koji ^a   Araki, Hirotaka ^a   Aoki, Tadashi ^a   Imada, Naoki ^a   Takada, Hitoshi ^a   Imaide, Yoichiroh ^a   Mikami, Kazuya ^a   Uchida, Mutsumi ^a   Saitoh, Masahito ^a   Miki, Tsuneharu ^a   more..

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Drug induced hepatopathy; Flutamide; Neoplasm; Prostate; Ursodeoxycholic acid

Indexed keywords

FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; URSODEOXYCHOLIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CARCINOMA; STATISTICAL ANALYSIS; VALIDATION PROCESS; CHEMICALLY INDUCED DISORDER; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FLUTAMIDE; HUMAN; LIVER DISEASES; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; URSODEOXYCHOLIC ACID; HUMANS;

EID: 0036010624     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00412.x     Document Type: Article

References (16)

1. Flutamide hepatotoxicity
2. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
3. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis
4. Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid
5. Effect of ursodeoxycholic acid on hepatotoxicity induced by flutamide during the treatment of prostatic cancer. Nishinihon
6. Comparison of various assay systems for prostate specific antigen standardization
7. A biological profile of a nonsteroidal antiandrogen, SCH13521 (4′-nitro-3′-trifluoromethylisobutyranilide)
8. Toxicity of anti-androgen flutamide in isolated rat hepatocytes
9. Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer
10. Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study
11. Ursodeoxycholic acid in the treatment of flutamide-induced hepatotoxicity. Nishinihon
12. Changes in liver function induced by flutamide in patients with prostate cancer. Studies in patients treated with total androgen blockage
13. Risk factor of liver disorders caused by flutamide. Statistical analysis using multivariate logistic regression analysis
14. Improvement of flutamide-induced hepatotoxicity by ursodeoxycholic acid in male rats